Arcutis Biotherapeutics announced that the Journal of Clinical and Aesthetic Dermatology published outcomes of an evaluation by a dermatologist panel on ZORYVE foam, a treatment for seborrheic dermatitis. The panel's review supports its use across all skin and hair types, with eight of nine experts expressing high confidence in prescribing it. ZORYVE's formulation, including Crodafos™ CES, is deemed suitable for diverse patients, including those with previous hair treatments.